A Study to Learn About the Effectiveness of Etrasimod in People With Ulcerative Colitis

Exclusion Criteria

• •Presence of clinical findings suggestive of Crohn's disease.
• •Severe extensive colitis evidenced by:
• •1. Physician judgement that the patient is likely to require hospitalization for medical or surgical intervention of any kind for UC (eg, colectomy) within 12 weeks.
• •2. Current evidence of acute severe UC, fulminant colitis, or toxic megacolon 3. Patients with a stoma or planned UC surgical intervention requiring hospitalization.
• •4\. Prior/Concomitant Therapy:
• •<!-- -->
• •1. any previous exposure to etrasimod including participation in the etrasimod clinical program.
• •2. any co-medication with one of the following conventional therapies: methotrexate or a thiopurine (azathioprine, mercaptopurine or tioguanine) or with any of the following advanced therapies for UC: biologics (a TNF, integrin or cytokine antagonist); JAK inhibitors (filgotinib, tofacitinib or upadacitinib) or with any other S1P receptor modulator.
• •Not owning a digital device with internet connection and/or not willing to complete health questionnaires on this device or not capable of using the health questionnaire collection tool.
• •Investigator site staff or Pfizer employees directly involved in the conduct of the study, site staff otherwise supervised by the investigator, and their respective family.